Article citationsMore>>
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., Eek, R., Horai, T., Noda, K., Takata, I., Smit, E., Averbuch, S., Macleod, A., Feyereislova, A., Dong, R.P. and Baselga, J. (2003) Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer (The IDEAL 1 Trial). Journal of Clinical Oncology, 21, 2237-2246.
http://dx.doi.org/10.1200/JCO.2003.10.038
has been cited by the following article:
-
TITLE:
Phase II Study of Carboplatin and Pemetrexed Followed by Gefitinib for Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive EGFR Mutation
AUTHORS:
Saki Manabe, Fumihiro Oshita, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito, Takeshi Kaneko, Kouzo Yamada
KEYWORDS:
Pemetrexed, Gefitinib, EGFR Mutation, Non-Small Cell Lung Cancer, Chemotherapy
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.6 No.15,
December
14,
2015
ABSTRACT: We conducted a phase II study of combination chemotherapy with
carboplatin (Cb) and pemetrexed (Pem) followed by gefitinib (Gef) to determine
the effects and toxicities in patients with non-small cell lung cancer (NSCLC)
harboring sensitive EGFR mutation. Eligible patients received four courses of
Cb at a dose corresponding to a target area under the curve equal to 6 mg/mL·min and 500 mg/m2 Pem on day 1 every
three to four weeks followed by sequential Gef 250 mg once a day until tumor
progression. Sixteen of registered 28 patients responded to Cb and Pem
combination. Twenty-seven patients received sequential Gef and 8 non-responders
to Cb and Pem achieved PR. The overall response rate was 85.7%. Among the major
toxicities, grade 3 SGPT elevation, nausea and thrombosis were observed in 3, 3
and 1 patients, respectively, who received Cb and Pem, and grade 3 SGPT
elevation and dry skin were observed in 5 and 1 patients, respectively, who
received Gef. There was no febrile neutropenia and no treatment-related death.
The median progression-free survival time was 19.1 months. Among 21 patients
who were followed up for more than 2 years, 14 survived during that time. Cb
and Pem followed by Gef maintenance are recommended for further evaluation for
patients with metastatic NSCLC harboring sensitive EGFR mutation.
Related Articles:
-
Tetsuya Kubota, Yoshio Okano, Mizu Sakai, Takashi Yamane, Naoki Shiota, Hiroshi Ohnishi, Hisanori Machida, Nobuo Hatakeyama, Eiji Takeuchi, Tomoyuki Urata, Fumitaka Ogushi, Akihito Yokoyama
-
Saki Manabe, Fumihiro Oshita, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito, Takeshi Kaneko, Kouzo Yamada
-
Mikhail N. Shapetska, Evelina V. Krupnova, Alena P. Mikhalenka, Natalia V. Chebotareva, Anna N. Shchayuk, Svetlana G. Pashkevich, Alexander V. Prokhorov
-
Guillermo López Vivanco, Eider Azkona, Sergio Carrera, Aintzane Sancho, Itziar Rubio, Juan Manuel Mañé, Begoña Calvo, Unai Aresti, Aitziber Buque, Inés Marrodán, Alberto Muñoz
-
Milan Rancic, Lidija Ristic, Marina Cekic, Tatjana Pejcic